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would seem most relevant to different stakeholders. Methods: A landscape review 
was performed in Medline and EMBASE. Initial search retrieved over 2000 articles. 
After a selection based on reference to healthcare, policy issues, or social justice, 
64 papers were included. Data were extracted and a full table was made, including 
all arguments found; next, identical or largely overlapping criteria were excluded 
and a reduced set was compiled. Results: The final set included 26 arguments, 
categorized by type (clinical, social justice, ethical, and policy). Examples of argu-
ments included in the final set are: Longevity, need, dignity and public health value. 
For each argument, relevance to stakeholders was scored on three levels (not, partly, 
and completely relevant). ConClusions: Many arguments play a role in making 
decisions about patient treatments, but not all are relevant to all interventions. 
Moreover, they may interact with each other. Therefore, systematic and analytical 
approaches such as multi-criteria decision analysis may be not suitable. As such, a 
viable way to deal with interacting and possibly conflicting arguments might be to 
arrange public discussions that would evoke different stakeholders’ perspectives.
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objeCtives: FDA breakthrough therapy designation was created in 2012 to expedite 
the registration of new health care technologies for use by patients with serious or 
life-threatening diseases/conditions. Breakthrough therapies are eligible for other 
FDA regulatory programs such as fast track designation, accelerated approval and 
priority review. We sought to determine whether other regulators and HTA agen-
cies/payers also sought to expedite access to these therapies. Methods: The FDA 
website was examined to identify breakthrough therapy medicines that had been 
approved up to 31 December 2014. The websites of the EMA (EU), Health Canada and 
TGA (Australia) were examined to determine their corresponding registration status. 
The NICE (England), IQWiG (Germany), TC (France), CADTH/pCODR (Canada) and 
PBAC (Australia) websites were examined to determine if and when the medicines 
had been considered for reimbursement/coverage. Results: The FDA approved 
14 breakthrough medicines as at 31 December 2014 for use in 16 unique patient 
populations (i.e. pairings). The mean time from submission to approval was 164 
days. Twelve pairings are orphan drugs and 9 are for patients with cancer. As of 
20 June 2015, 13 had been registered in the EU (mean time 326 days), 8 in Canada 
(275 days) and 9 in Australia (N/A). Four of the 15 pairings had been assessed by 
NICE (all recommended), 5 by IQWiG (4 additional benefit not quantifiable, 1 minor 
additional benefit), 6 by the TC (ASMR rating = II (2), III (1), IV (1), V (2)), 8 by CADTH/
pCODR (6 recommended, 2 not recommended) and 7 by the PBAC (all recom-
mended). ConClusions: Most of the 16 pairings were registered first in the US. 
The FDA evaluation period was shorter compared to other regulatory agencies. Some 
HTA agencies are yet to consider many pairings whilst others have dissimilar views 
on their additional clinical benefit.
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objeCtives: This research aims to characterize the extent to which health tech-
nology assessment (HTA) is currently being used to determine pharmaceutical 
coverage in the Middle East and North Africa (MENA) region. The objectives are 
to understand which decision-makers are currently undertaking this activity, the 
extent of its formalization, and in which parts of the healthcare system in each 
country there is greatest appetite for its implementation. Methods: In-depth, 
qualitative interviews were conducted with a total of 11 payer decision-makers 
and 20 industry stakeholders in Egypt, Saudi Arabia, Turkey and the United Arab 
Emirates (UAE). Published literature and government websites were also reviewed. 
Primary and secondary research focused on current and evolving reimbursement 
decision-making procedures in these countries in addition to potential policy 
reforms. Results: Of the countries considered, HTA focused on evaluation of 
specific pharmaceuticals appears to have gained the most traction in Saudi Arabia, 
where one of the public-sector payers has begun undertaking in-depth pharma-
coeconomic (PE) analysis. In Egypt, while a PE unit has been established, its pre-
sent role is to support the country’s Drug Pricing Committee on a case-by-case 
basis. In Turkey, while PE data is required for reimbursement submission, budget 
impact is reported to remain the primary driver of national-level decision-mak-
ing. Meanwhile, in the UAE, there is little evidence that the insurers increasingly 
responsible for coverage under the country’s healthcare reforms are using formal 
HTA. ConClusions: The extent of HTA formalization and the specific areas of 
the healthcare system in which HTA operates vary across the MENA region, in 
line with the broader policy framework. Champions of further HTA development 
come from diverse stakeholder groups in each country. With time, it is expected 
that HTA will gain increasing traction across MENA, alongside arrangements 
such as risk-sharing schemes, with significant consequences for pharmaceutical 
access.
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objeCtives: Examine orphan drugs assessed by the German Federal Joint 
Committee (G-BA) between January 2011 and May 2015 and compare their 
assessments with those of other international HTA agencies. Methods: GBA 
guidlines and pricing and reimbursement legislation. Results: The survey analyses 
pharmacoeconomic guideline of the National Council on prices and reimburse-
ment for inclusion of new INN in the positive drug list in Bulgaria. Requirements 
for efficacy, safety, benefits, adverse events, comparator, standard treatment, drug 
utilization, budget impact, patient population during the premarketing and post-
marketing period are change in order to provide data with higher quality for the 
decision making process . From April 2013 to July 2015. Over that period more than 
36 new INNs were accepted for reimbursement in Bulgaria. A guideline with an HTA 
approach for assessment of submitted dossiers was introduced in April 2015 The 
experience in that field of other MSs is summarized and compared. ConClusions: 
The study evaluates how NCPR develops recommendations and reimbursement 
decisions on the basis of one step procedure which shortens the pricing and reim-
bursement process in comparison with other EU MSs. No published criteria how to 
evaluate the submitted pharmacoeconomic information by the expert of the NCPR 
are publicly available and HTA appraisal may be subjectively biased.
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objeCtives: For orphan drugs an additional benefit is granted by market authori-
zation of the EMA. In case orphan drugs exceed an annually turnover of 1m Euro 
(based on ex. pharmacy prices) in the outpatient sector recently authorized orphan 
drugs have to undergo an assessment of the additional benefit extent by the Federal 
Joint Committee. Based on the results pharmaceutical manufacturer and the head 
association of the statutory health insurance negotiate rebates. The objective of this 
analysis is to assess whether the additional benefit extent of orphan drugs does 
impact the rebate size of the price negotiations. Methods: In a first step orphan 
drugs affected by an assessment of additional benefit extent were analyzed within 
the German market. The dependency between additional benefit extent and rebate 
size of negotiations is assessed by correlation analysis. This analysis is based on 
relevant public available data of the Federal Joint Committee as well as price related 
rebate information related to the AMNOG process for orphan drugs. Results: By 
May 2015, 10 of currently 77 in Germany registered orphan drugs passed the AMNOG 
legislation comprising the assessment of additional benefit extent as well as associ-
ated price negotiations. Thereby rebates sizes ranging from 9% up to almost 44%. 
The analysis of the additional benefit extent and the rebate size showed no correla-
tion between the two parameters. ConClusions: The hypothesis of an inversely 
proportional dependence between additional benefit extent and rebate size was 
refuted by this analysis. Following this a larger benefit extent tends not to impact 
price negotiations in terms of a rebate reduction. However, the small sample size 
tends to limit power of the analysis.
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objeCtives: Canadian provinces are encouraged to follow HTA recommendations 
conducted under pCODR for cancer drugs, but have ultimate authority over the 
final reimbursement decision on public drug plans. In order to understand the 
impact of HTA assessments on market access of oncology drugs and highlight vari-
ations across the individual jurisdictions we conducted a quantitative analysis of 
all pCODR’s oncology assessments completed in 2013-14 and consequent fund-
ing decisions implemented by the provinces. Methods: Data, obtained from the 
pCODR database for all 27 assessments completed in 2013 and 2014, were used to 
estimate median time to pCODR final decision and the time to first funding approval 
in one of the nine provinces excluding Quebec. We also examined the probability 
of obtaining public drug plan approval in Canada based on the pCODR recommen-
dation. Results: On average, 74% of the assessments resulted in a favourable 
decision by the provinces, compared to 88% with a favourable pCODR recommen-
dation. However, positive provincial funding decisions varied considerably (88% in 
Ontario, Manitoba, and Saskatchewan, to 32% in Prince Edward Island). At the time 
of analysis 16% of drugs were still awaiting provincial funding assessment, while 
10% received no funding primarily after a “no funding” pCODR recommendation. 
The median time between marketing approval and a final pCODR decision was 200 
days; the median time between that final decision and receiving the first fund-
ing approval was 115 days. Provincial funding decisions under pCPA joint negotia-
tions took longer (median of 118 days) compared to those negotiated separately (80 
days). ConClusions: It takes nearly four months for provinces to begin funding 
new drugs after a final HTA decision is issued, with funding decisions in other 
jurisdictions lagging further behind. Multiple levels of pricing and reimbursement 
regulations and a highly fragmented pharmaceutical market are likely impacting 
market access for new drugs in Canada.
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objeCtives: The healthcare sector is evolving while life expectancy is increasing. 
These trends put greater pressure on resources, prompt reforms, and demand trans-
parent arguments and criteria to assess the overall value of health interventions. 
Besides (cost) effectiveness, many criteria play a role when determining the value 
of interventions. There is no consensus on the core arguments. This study aimed at 
retrieving the most widely recognized arguments used in making decisions about 
patient treatments and prioritizing interventions, and to compile a smaller set that 
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the Decision Resources Group’s ‘Global Market Access Solution’ database were 
reviewed. Results: The healthcare systems in Brazil, Argentina and Mexico are 
decentralised, while that of Colombia is centrally managed. All countries have a 
national health service for all residents, but the proportion of the population that 
relies solely on this varies greatly between countries. In Brazil, 25% of the popula-
tion has private health insurance, while only a small proportion of the popula-
tion relies on private insurance in the other countries. In Mexico and Argentina, 
residents in formal employment are obliged to enrol in one of the social security 
sponsored schemes. In Brazil, Argentina and Colombia, national formularies include 
the mandatory minimum healthcare provision. In Mexico, the national formulary 
is not binding and the different social security schemes decide which treatments 
to cover. The role of health technology assessment (HTA) in the reimbursement 
process varies in different countries. In Brazil, Mexico and Colombia, HTA is criti-
cal in the reimbursement decision process, while in Argentina it has been mostly 
used to assess treatments for catastrophic illnesses; although there is a drive to 
include HTA in the decision process. Opportunities include a growing demand for 
pharmaceuticals, and challenges include decentralised healthcare systems and high 
use of generics. ConClusions: Most countries have a decentralised system where 
reimbursement decision making occurs at the regional level or at the social security 
funds level. HTA is critical in decision making in Brazil, Mexico and Colombia, but 
not yet in Argentina. We have identified current opportunities and challenges for 
the different countries.
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bACkgRound: Evidence bases medicine is the governing principle ruling all aspects 
of a new medical product. Marketing authorization organizations and health tech-
nology agencies focused on the reimbursement aspects of a new product are both 
relying in their decision making process on clinical data of the highest possible 
evidence. While marketing authorization is an increasingly international process 
with standardized rules, the reimbursement process is conducted on a national 
level with country-specific requirements. In some indications, e.g. in chronic dis-
eases, where it is difficult to recruit newly diagnosed patients for clinical trials, 
establishing the efficacy of a product against placebo is a common approach, as 
only patients who did not succeed with the available treatment options are willing 
to participate in these trials. objeCtives: To review the national requirements for 
the reimbursement of new medical products with a positive centralized marketing 
authorization based on placebo-controlled clinical trials. We will demonstrate that 
the acceptance of placebo-controlled trials is handled differently between coun-
tries and that different strategies to process these data are necessary. Methods: 
We focused on the national health technology agencies of five representative 
European countries, including the United Kingdom, France, Germany, Sweden and 
the Netherlands. A targeted desktop research on the published methodology and 
the decisions regarding medical products with a marketing authorization based 
on placebo controlled trials for the most recent years was conducted. Results: 
The methodological requirements to get reimbursement for a medical product 
with a marketing authorization based on placebo-controlled trials are different 
in these countries, leading to heterogeneous decisions. ConClusions: Getting a 
positive decision for reimbursement is challenging for products which have mar-
keting authorization based on placebo-controlled trials. The national requirements 
and thresholds for reimbursement are very different and highly dependent on the 
governing principle for evaluation, ranging from quality of life based decisions to 
comparator driven additional benefit decisions.
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objeCtives: Resolutions on early benefit assessment can be granted with a time 
restriction, termed “limited”. As a consequence companies are required to resubmit 
their data later. The objective of the present study was to assess reasons for limita-
tion. Methods: The following three criteria are given for limiting a resolution: 
incomplete data on patient relevant endpoints, limited quality of evidence, and 
missing data can be provided at a later stage. Assessment was based on resolutions 
with limitations published until June 2016. For each resolution reasons for limita-
tions were identified and requirements for a resubmission were captured using 
supporting documents (“Tragende Gruende”). Results: 26 out of 130 resolutions 
(20%) were limited with limitations ranging from 1 to 5 years. In 18 resolutions (69%) 
G-BA made reference to missing data on endpoints. In further 18 resolutions the 
G-BA explicitly referred to limited quality of evidence. Expectations for better data 
in the future are mentioned in 13 resolutions (50%). More information on what data 
is required for a reassessment is provided in 8 resolutions (31%). ConClusions: 
Most limitations are made even though they do not meet (all) legal criteria. Missing 
information on the requirements for reassessment increases the risk for subse-
quent failure.
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objeCtives: The use of innovative medicines has been associated with increased 
healthcare-related expenditure in the EU5 (Italy, France, Spain, UK and Germany). 
In some countries, this has raised concerns over the clinical and economic assess-
ment of such medicines and has led to the introduction of additional criteria to 
orphan drugs assessments between January 2011 and May 2015 and compari-
son with assessments conducted by HTA agencies in France, Netherlands, the 
UK and Canada, to examine similarities and differences in benefit evaluations, 
reimbursement and drug access. Results: Germany has 23 completed assess-
ments for 21 orphan drugs during the time frame. 9 received non quantifiable 
additional benefit, 11 marginal and 3 significant. Out of 5 drugs where different 
patient subgroups were identified, only 1 (ivacaftor) received different ratings 
across two patient subgroups (marginal and significant). This 21 orphan drug 
sub-set was then compared across the other countries. In France, 19 (90.5%) were 
recommended for reimbursement. Comparing the additional benefit ratings 
assigned in Germany with the French ASMR ratings, we found significantly dif-
ferent value assessments for 15 (78.9%) out of 19 drugs reviewed in both countries. 
In the Netherlands, HTA’s by the National Health Care Institute were available for 
7 (33.3%) drugs: 5 (23.8%) were reimbursed, all with restrictions. SMC reviewed 14 
(66.7%) drugs of which 5 (23.8%) were not recommended (3: non-submission and 2: 
economic considerations). Of the 9 (42.9%) drugs that were recommended, 6 had a 
negotiated patient access scheme (PAS). NICE reviewed 5 (23.8%) drugs, 4 of which 
were for oncology and not recommended for reimbursement. Only one (4.8%) 
drug (pirfenidone) was recommended for restricted use based on a PAS. Canada’s 
CADHT assessed 6 (28.6%) drugs: only 4 (19.0%) were listed with restrictions after 
price reductions. ConClusions: Among the countries examined, Germany had 
the highest number of orphan drugs assessed. Differences in HTA assessment 
criteria lead to noticeably different benefit evaluations, recommendations and, 
ultimately, drug access.
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objeCtives: The primary focus of manufacturers’ reimbursement submissions in 
Germany is on demonstrating the added benefit of a product versus the appropri-
ate comparator(s). Some decisions made by Gemeinsamer Bundesausschuss (G-BA) 
result in a time-limited approval, after which there should be a review. This study 
analyses any completed reviews conducted by the G-BA. Methods: G-BA deci-
sions were searched to identify restricted decisions and subsequent reviews. Data 
were extracted, the reasons for the restrictions and the ways these were addressed 
in the reviews, were analysed. Results: 20% (27/135) of all decisions identified 
were time restricted. Restrictions were mainly applied to products with small or 
no added benefit. The most common reason for a restriction was incomplete evi-
dence profiles, and the most common restriction period was three years. Of the 27 
restrictions identified, two reviews have taken place, two restriction periods have 
been extended and five more decisions are expected by the end of 2015. An analysis 
of the completed eribulin review showed that the manufacturer was granted suf-
ficient time to collect additional evidence and that the G-BA adjusted its recom-
mendations in a favourable manner once further evidence was provided. However, 
during the vemurafenib review the level of added benefit did not change from the 
original evaluation. This indicates the manufacturer did not present sufficient data 
to address the original criticism and was therefore unable to raise the level of added 
benefit. Furthermore, it is evident that the G-BA takes regulatory guidance into con-
sideration in decision making. ConClusions: The results indicate that restricted 
decisions provide manufacturers with the opportunity to collect additional data 
and improve the final added benefit recommendation. If manufacturers address 
the G-BA’s criticism of the original submission, more favourable added benefit levels 
can be achieved during the review. Furthermore, it shows that EMA decisions influ-
ence G-BA decision making.
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objeCtives: Benefit assessment usually requires RCT data. Orphan drugs are 
granted additional benefit by law, but not drugs with conditional or exceptional 
approval or PUMA. The objective of this study was to assess how their status is 
handled in benefit assessment. Methods: All resolutions until June 2016 were 
analyzed whether they have been approved by EMA under these circumstances. 
Those which do were assessed regarding underlying evidence, extend of additional 
benefit and other aspects of the resolution. Results: 7 out of 104 resolutions (7%) 
met these criteria – 5 with conditional approval, 1 with exceptional circumstances 
and 1 PUMA. 2 out of 7 products had only non-RCT evidence. For 6 products the 
IQWiG found no additional benefit and for 1 product a major additional benefit. The 
G-BA increased three products to minor (or considerable) additional benefit, even 
though one approval was based only on a case series. However, for three products 
the result was still “additional benefit not proven”. 4 out of 7 resolutions had been 
limited. ConClusions: Special regulatory status gives no formal advantage in 
benefit assessment. However G-BA seems to take their status into account and 
using limitations to account for future evidence.
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objeCtives: To define the current processes and key decision makers involved 
in gaining market access in Brazil, Argentina, Mexico and Colombia, and identify 
opportunities and challenges to market access in these countries. Methods: 
The websites of the appropriate authorities and agencies in each country and 
